Cargando…
Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury
BACKGROUND: Nephrotoxic drug prescription may contribute to acute kidney injury (AKI) occurrence and worsening among critically ill patients and thus to associated morbidity and mortality. The objectives of this study were to describe nephrotoxic drug prescription in a large intensive-care unit coho...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757082/ https://www.ncbi.nlm.nih.gov/pubmed/31549274 http://dx.doi.org/10.1186/s13613-019-0580-1 |
_version_ | 1783453512268513280 |
---|---|
author | Ehrmann, Stephan Helms, Julie Joret, Aurélie Martin-Lefevre, Laurent Quenot, Jean-Pierre Herbrecht, Jean-Etienne Benzekri-Lefevre, Dalila Robert, René Desachy, Arnaud Bellec, Fréderic Plantefeve, Gaëtan Bretagnol, Anne Dargent, Auguste Lacherade, Jean-Claude Meziani, Ferhat Giraudeau, Bruno Tavernier, Elsa Dequin, Pierre-François |
author_facet | Ehrmann, Stephan Helms, Julie Joret, Aurélie Martin-Lefevre, Laurent Quenot, Jean-Pierre Herbrecht, Jean-Etienne Benzekri-Lefevre, Dalila Robert, René Desachy, Arnaud Bellec, Fréderic Plantefeve, Gaëtan Bretagnol, Anne Dargent, Auguste Lacherade, Jean-Claude Meziani, Ferhat Giraudeau, Bruno Tavernier, Elsa Dequin, Pierre-François |
author_sort | Ehrmann, Stephan |
collection | PubMed |
description | BACKGROUND: Nephrotoxic drug prescription may contribute to acute kidney injury (AKI) occurrence and worsening among critically ill patients and thus to associated morbidity and mortality. The objectives of this study were to describe nephrotoxic drug prescription in a large intensive-care unit cohort and, through a case–control study nested in the prospective cohort, to evaluate the link of nephrotoxic prescription burden with AKI. RESULTS: Six hundred and seventeen patients (62%) received at least one nephrotoxic drug, among which 303 (30%) received two or more. AKI was observed in 609 patients (61%). A total of 351 patients were considered as cases developing or worsening AKI a given index day during the first week in the intensive-care unit. Three hundred and twenty-seven pairs of cases and controls (patients not developing or worsening AKI during the first week in the intensive-care unit, alive the case index day) matched on age, chronic kidney disease, and simplified acute physiology score 2 were analyzed. The nephrotoxic burden prior to the index day was measured in drug.days: each drug and each day of therapy increasing the burden by 1 drug.day. This represents a semi-quantitative evaluation of drug exposure, potentially easy to implement by clinicians. Nephrotoxic burden was significantly higher among cases than controls: odds ratio 1.20 and 95% confidence interval 1.04–1.38. Sensitivity analysis showed that this association between nephrotoxic drug prescription in the intensive-care unit and AKI was predominant among the patients with lower severity of disease (simplified acute physiology score 2 below 48). CONCLUSIONS: The frequently observed prescription of nephrotoxic drugs to critically ill patients may be evaluated semi-quantitatively through computing drug.day nephrotoxic burden, an index significantly associated with subsequent AKI occurrence, and worsening among patients with lower severity of disease. |
format | Online Article Text |
id | pubmed-6757082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-67570822019-10-07 Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury Ehrmann, Stephan Helms, Julie Joret, Aurélie Martin-Lefevre, Laurent Quenot, Jean-Pierre Herbrecht, Jean-Etienne Benzekri-Lefevre, Dalila Robert, René Desachy, Arnaud Bellec, Fréderic Plantefeve, Gaëtan Bretagnol, Anne Dargent, Auguste Lacherade, Jean-Claude Meziani, Ferhat Giraudeau, Bruno Tavernier, Elsa Dequin, Pierre-François Ann Intensive Care Research BACKGROUND: Nephrotoxic drug prescription may contribute to acute kidney injury (AKI) occurrence and worsening among critically ill patients and thus to associated morbidity and mortality. The objectives of this study were to describe nephrotoxic drug prescription in a large intensive-care unit cohort and, through a case–control study nested in the prospective cohort, to evaluate the link of nephrotoxic prescription burden with AKI. RESULTS: Six hundred and seventeen patients (62%) received at least one nephrotoxic drug, among which 303 (30%) received two or more. AKI was observed in 609 patients (61%). A total of 351 patients were considered as cases developing or worsening AKI a given index day during the first week in the intensive-care unit. Three hundred and twenty-seven pairs of cases and controls (patients not developing or worsening AKI during the first week in the intensive-care unit, alive the case index day) matched on age, chronic kidney disease, and simplified acute physiology score 2 were analyzed. The nephrotoxic burden prior to the index day was measured in drug.days: each drug and each day of therapy increasing the burden by 1 drug.day. This represents a semi-quantitative evaluation of drug exposure, potentially easy to implement by clinicians. Nephrotoxic burden was significantly higher among cases than controls: odds ratio 1.20 and 95% confidence interval 1.04–1.38. Sensitivity analysis showed that this association between nephrotoxic drug prescription in the intensive-care unit and AKI was predominant among the patients with lower severity of disease (simplified acute physiology score 2 below 48). CONCLUSIONS: The frequently observed prescription of nephrotoxic drugs to critically ill patients may be evaluated semi-quantitatively through computing drug.day nephrotoxic burden, an index significantly associated with subsequent AKI occurrence, and worsening among patients with lower severity of disease. Springer International Publishing 2019-09-23 /pmc/articles/PMC6757082/ /pubmed/31549274 http://dx.doi.org/10.1186/s13613-019-0580-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Ehrmann, Stephan Helms, Julie Joret, Aurélie Martin-Lefevre, Laurent Quenot, Jean-Pierre Herbrecht, Jean-Etienne Benzekri-Lefevre, Dalila Robert, René Desachy, Arnaud Bellec, Fréderic Plantefeve, Gaëtan Bretagnol, Anne Dargent, Auguste Lacherade, Jean-Claude Meziani, Ferhat Giraudeau, Bruno Tavernier, Elsa Dequin, Pierre-François Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury |
title | Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury |
title_full | Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury |
title_fullStr | Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury |
title_full_unstemmed | Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury |
title_short | Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury |
title_sort | nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757082/ https://www.ncbi.nlm.nih.gov/pubmed/31549274 http://dx.doi.org/10.1186/s13613-019-0580-1 |
work_keys_str_mv | AT ehrmannstephan nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT helmsjulie nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT joretaurelie nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT martinlefevrelaurent nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT quenotjeanpierre nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT herbrechtjeanetienne nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT benzekrilefevredalila nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT robertrene nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT desachyarnaud nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT bellecfrederic nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT plantefevegaetan nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT bretagnolanne nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT dargentauguste nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT lacheradejeanclaude nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT mezianiferhat nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT giraudeaubruno nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT tavernierelsa nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT dequinpierrefrancois nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury AT nephrotoxicdrugburdenamong1001criticallyillpatientsimpactonacutekidneyinjury |